Regulation · Australia

Is retatrutide legal
in Australia?

Retatrutide is an investigational Eli Lilly drug, approved nowhere, and Australia’s Poisons Standard does not name it. The TGA has still said a good deal about it. Here are its words, the law it cites and the dated record.

Short answerRegulation · 7 min read · Updated 18 Nov 2026

Retatrutide is not approved in Australia: the TGA says it has not been approved “by the TGA or any comparable international regulator”. TGA advertising guidance says GLP-1 receptor agonists are prescription-only medicines, including “derivatives of semaglutide or dulaglutide such as retatrutide”. Under the Therapeutic Goods Act 1989, supplying unapproved therapeutic goods is an offence unless an exemption applies.

Key takeaways

  • The TGA wrote on 5 November 2026 that retatrutide “is still undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator”.
  • The October 2026 Poisons Standard does not name retatrutide. The TGA’s advertising guidance says GLP-1 receptor agonists are regulated as prescription-only medicines and that this “includes derivatives of semaglutide or dulaglutide such as retatrutide”.
  • Under section 19B of the Therapeutic Goods Act 1989, importing, exporting, manufacturing or supplying therapeutic goods for use in humans that are not registered, listed, exempt or approved is an offence.
  • In 2026 the TGA named retatrutide in a seizure with NSW Police and in two laboratory findings on products sold under its name: one held semaglutide and no retatrutide, and products from one brand held less than their labels stated.
  • WADA’s Prohibited List does not name retatrutide, but class S0 covers substances with no current government approval for human therapeutic use, WADA says a peptide not named on the List “may still be prohibited”, and anti-doping bodies decide how it applies.

01Is retatrutide approved in Australia?

No. The Therapeutic Goods Administration (TGA) said so in two safety advisories in late 2026, and Sport Integrity Australia’s page on retatrutide says the same.

On 5 November 2026 the TGA wrote that retatrutide “is still undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator”, and that any retatrutide product accessed outside a clinical trial “could be counterfeit”. Its advisory of 14 September 2026 used the same status words.

In the TGA’s April 2026 definition, unapproved peptide products “are goods which have not been included in the ARTG”, the Australian Register of Therapeutic Goods. The same advisory gives products containing retatrutide among its “examples of unapproved peptide products”, with those containing BPC-157, GHK-Cu, TB-500 and CJC-1295, “often supplied in injectable form”. Sport Integrity Australia: “Retatrutide is currently not approved by the TGA as a registered medicine.”

Retatrutide is an investigational Eli Lilly drug, approved nowhere. What its trials measured is in our retatrutide research guide.

02Does the Poisons Standard name retatrutide?

No. The instrument in force is the Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, which commenced on 1 October 2026. A full-text search of it for “retatrutide” and for its development code, LY3437943, finds nothing (18 Nov 2026).

The Standard does name three other GLP-1 receptor agonists, the active ingredients of approved prescription medicines: dulaglutide, semaglutide and tirzepatide, each in Schedule 4, “Prescription only medicines”.

The TGA’s view. The TGA’s advertising guidance, last updated on 11 March 2025, says that semaglutide, tirzepatide and dulaglutide “are regulated as prescription-only medicines”, and adds: “This includes derivatives of semaglutide or dulaglutide such as retatrutide.”

The Standard’s rule on derivatives. Section 7 says that, unless the contrary intention appears, a reference to a substance includes “every salt, active principle or derivative of the substance”. The introduction adds that a substance “is not classed as a derivative on the basis of a single, prescriptive set of criteria”; the test is a balanced look at whether it has “a similar nature (e.g. structurally, pharmacologically, and toxicologically)” to a scheduled poison.

We draw no conclusion of our own on how retatrutide is scheduled. The guidance above is the TGA’s stated position.

DocumentWhat it says about retatrutide
Poisons Standard, October 2026Not named (full-text search, 18 Nov 2026)
Poisons Standard, section 7A reference to a substance includes “every salt, active principle or derivative of the substance”
TGA advertising guidance, updated 11 Mar 2025“This includes derivatives of semaglutide or dulaglutide such as retatrutide”; it is “an unapproved therapeutic good”
TGA safety advisories, 14 Sep and 5 Nov 2026Not approved “by the TGA or any comparable international regulator”
Therapeutic Goods Act 1989, s 19BAn offence to import, export, manufacture or supply therapeutic goods for use in humans that are not registered, listed, exempt or approved

03What does the Therapeutic Goods Act say?

Scheduling decides who may supply and possess a substance. The Therapeutic Goods Act 1989 decides whether a product may be on the market at all.

Therapeutic goods. The Act’s definition of “therapeutic use” includes “influencing, inhibiting or modifying a physiological process in persons”. The TGA’s April 2026 advisory states that under the Act “peptide products are regulated as therapeutic goods in Australia”.

The core offence. Section 19B makes it an offence to import, export, manufacture or supply in Australia therapeutic goods for use in humans unless they are registered or listed, exempt, or approved under section 19 or 19A. The maximum is 12 months’ imprisonment, 1,000 penalty units or both. It rises to 5 years, 4,000 penalty units or both where use of the goods has resulted in, or is likely to result in, harm or injury.

The TGA’s summary. Its September 2026 advisory on retatrutide says: “The supply and advertising of unapproved therapeutic goods in Australia is prohibited unless a relevant exemption applies.” It lists infringement notices, direction or prevention notices, and civil or criminal penalties, and says penalties for breaches of the Act include “civil penalties of up to $1.82 million per breach for individuals or $18.2 million per breach for corporations, and criminal penalties of up to 7 years imprisonment” (amounts in Australian dollars).

Advertising. The TGA’s guidance gives its reason for retatrutide: “because it is an unapproved therapeutic good and unapproved therapeutic goods cannot be advertised unless exempt.”

Labels. The April 2026 advisory: “Disclaimers that a product is for ‘research use only’ does not make its supply lawful.” Such disclaimers alone do not “change a product’s regulatory status”, “permit importation” or “remove advertising or supply obligations”. More: what “research use only” means. The rules for every peptide are on are peptides legal in Australia?

04What has the TGA done about retatrutide, and when?

A dated record from the TGA’s own documents. Each entry names retatrutide unless marked.

DateWhat happened
11 Mar 2025TGA advertising guidance, last updated on this date, says GLP-1 receptor agonists are regulated as prescription-only medicines, including “derivatives of semaglutide or dulaglutide such as retatrutide”
13 Apr 2026A TGA safety advisory gives products containing retatrutide among its examples of unapproved peptide products, “often supplied in injectable form”
4 Aug 2026With NSW Police, the TGA executes search warrants at two residential premises allegedly linked to a social media influencer (announced 17 Aug)
17 Aug 2026The TGA announces the seizure of more than A$120,000 of peptide and anabolic steroid products that the influencer allegedly imported and relabelled; “The products include retatrutide”
14 Sep 2026After a report of a serious adverse effect, TGA testing of a product sold as retatrutide finds “undeclared semaglutide and no retatrutide”
1 Oct 2026The October 2026 Poisons Standard commences. It does not name retatrutide
5 Nov 2026TGA testing of products from one brand, sold as retatrutide and identified in a New South Wales police investigation, finds they “contained less retatrutide than stated on the label, with significant variation between samples”
18 Nov 2026Our check: no Poisons Standard entry; the TGA’s status wording unchanged in the newest captures we read

The TGA concluded in November that consumers cannot rely on these labels to know what substance, or what amount, a product contains. Other cases: contamination and mislabeling.

05How is retatrutide treated in Australian sport?

Sport Integrity Australia’s page on retatrutide says, under the 2026 Prohibited List: “Retatrutide is not listed on the Prohibited List.” The same page warns that counterfeit peptides, “including retatrutide, are being sold online illegally”, and that “there is also a possibility that these peptides are contaminated with prohibited substances, which could result in athletes committing an Anti-Doping Rule Violation (ADRV).”

Its peptides page gives products containing retatrutide, GHK-Cu or melanotan II as examples of unapproved peptide products, which it defines as goods not included in the Australian Register of Therapeutic Goods, and says they “can also be illegal and/or prohibited for use in sport”.

“Not listed” is not the whole answer. Class S0 of WADA’s List covers any pharmacological substance not addressed elsewhere on it and with “no current approval by any governmental regulatory health authority for human therapeutic use”; WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”; and anti-doping organisations decide how it applies. We draw no conclusion for retatrutide here. The detail: is retatrutide banned in sport?

06What we don’t know

The ARTG itself. We could not search it, because tga.gov.au did not respond to our tools on 18 November 2026. The TGA’s own statements above say retatrutide is not approved.

A scheduling decision. Whether the TGA will name retatrutide in the Poisons Standard. The October 2026 Standard does not, and we could not search the TGA’s scheduling pages.

State and territory law. The TGA says these laws “may impose additional controls on the sale, supply and possession of unapproved peptide products”. We have not set them out.

The investigations. The TGA said on 5 November 2026 that NSW Police inquiries “remain ongoing”. The August seizure is described as allegedly linked to an influencer.

For the UK and US positions: is retatrutide legal in the UK? and is retatrutide legal in the US? Changes are logged in our regulatory changelog.

This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.

RefSources

  1. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327): sections 2 and 7, introduction, Schedule 4, index. Federal Register of Legislation, registered 30 Sep 2026, commenced 1 Oct 2026; full PDF downloaded through the legislation.gov.au API and searched, 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  2. Therapeutic Goods Administration. Advertising Ozempic and GLP-1 receptor agonists is prohibited. Advertising guidance, last updated 11 Mar 2025; read on the Internet Archive capture of 10 Jun 2026, the newest (tga.gov.au timed out on 18 Nov 2026). www.tga.gov.au/products/regulations-all-products/advertising…
  3. Therapeutic Goods Act 1989, section 3 (definitions) and section 19B. Federal Register of Legislation, Compilation No. 89 (5 Sep 2025), the latest; volume 1 PDF read 18 Nov 2026. www.legislation.gov.au/C2004A03952/latest/text
  4. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 Apr 2026; read on the Internet Archive capture of 10 Aug 2026, the newest. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  5. Therapeutic Goods Administration. TGA flexes its muscle against illegal peptides and steroids. Media release, 17 Aug 2026; read on the Internet Archive capture of 11 Oct 2026, the newest. www.tga.gov.au/news/media-releases/tga-flexes-its-muscle-aga…
  6. Therapeutic Goods Administration. TGA tests counterfeit retatrutide product following serious adverse event report. Safety advisory, 14 Sep 2026; read on the Internet Archive capture of 21 Sep 2026, the newest. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  7. Therapeutic Goods Administration. TGA testing finds unapproved peptides do not contain what their labels claim. Safety advisory, 5 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  8. Sport Integrity Australia. Retatrutide (substance education page; cites the 2026 Prohibited List). Read on the Internet Archive captures of 8 Jun, 14 Jul and 22 Oct 2026, the newest (sportintegrity.gov.au did not respond on 18 Nov 2026). www.sportintegrity.gov.au/what-we-do/anti-doping/substance-e…
  9. Sport Integrity Australia. Peptides explained (unapproved peptides). Substance education page; read on the Internet Archive capture of 5 Nov 2026, the newest. www.sportintegrity.gov.au/what-we-do/anti-doping/substance-e…
  10. World Anti-Doping Agency. The 2026 Prohibited List and the 2027 Prohibited List (in force 1 Jan 2027), class S0 and index. International Standard; both PDFs downloaded from wada-ama.org and searched, 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  11. World Anti-Doping Agency. 2027 Prohibited List: summary of major modifications and explanatory notes (S0, non-approved substances). Undated (the file name carries 17 Aug 2026); published with the 2027 List on 21 Sep 2026; read at wada-ama.org 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is retatrutide approved by the TGA?

No. The TGA wrote on 5 November 2026 that retatrutide is still in clinical trials in humans and “has not been approved by the TGA or any comparable international regulator”.

Is retatrutide prescription-only in Australia?

The TGA’s advertising guidance says GLP-1 receptor agonists are regulated as prescription-only medicines and that this “includes derivatives of semaglutide or dulaglutide such as retatrutide”. The October 2026 Poisons Standard does not name retatrutide itself, and we draw no scheduling conclusion of our own.

Can retatrutide be advertised in Australia?

The TGA says it cannot, “because it is an unapproved therapeutic good and unapproved therapeutic goods cannot be advertised unless exempt.”

Does a “research use only” label change retatrutide’s status in Australia?

No. The TGA says such a disclaimer does not make supply lawful, and that disclaimers alone do not change a product’s regulatory status, permit importation or remove advertising and supply obligations.

What did TGA testing find in products sold as retatrutide?

In September 2026, one product sold as retatrutide contained “undeclared semaglutide and no retatrutide”. In November 2026, tested products from one brand held less retatrutide than their labels stated, with significant variation between samples.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page